The race is on to get cell-based protein products – meat, seafood and dairy – onto supermarket shelves and into the hands of consumers.
Creating meat, fish or dairy products in a lab using animal cells, with no physical harm coming to those animals, may be seen as the extreme end of food innovation. However, such is the progress in the field we may be seeing cell-based, or cultivated, products on our supermarket shelves within a couple of years, if not sooner.
To get there, the businesses behind these initiatives (detailed below), will have to speed up production, reduce costs, get regulatory approval and convince retailers and consumers cultivated produce is every bit as tasty and nutritional as that from slaughtered animals.
Inroads are being made in some of these areas. A number of cell-based companies have trialled products in taste tests with consumers or potential foodservice partners. One – the US-based Eat Just – has had a cell-based chicken product approved by regulators in Singapore, the first jurisdiction to give lab-grown meat the green light.
There has been a ‘jam tomorrow’ feeling about promises made by cell-based companies in recent years when having a product ready for consumers always seems to be a year or so away but, with developments such as that in Singapore, we appear to be approaching a point where theory becomes reality.
Were such a thing to happen on a meaningful scale, the effect could be revolutionary for the food industry and for the planet.
Dutch cell-based protein business Mosa Meat can lay claims to being one of the elder statesmen of the cell-based meat movement having created the world’s first lab-cultivated beef hamburger back in 2013.
Perhaps as a result of that relative longevity and experience, it has attracted a lot of attention from investors, including Switzerland-based meat processor Bell Food Group, Nutreco, an animal nutrition and aquafeed specialist, and Jitse Groen, CEO of Just Eat Takeaway.com.
In early 2021, Mosa Meat announced it had raised another US$10m to complete an $85m Series B investment round.
The company said it will use the funds to extend a pilot production facility at its home in Maastricht, develop an industrial-sized production line and expand its team.
Formerly known as Memphis Meats, under which guise the West Coast US company attracted investors including meat giant Tyson Foods, agri-food giant Cargill and businessmen Richard Branson and Bill Gates.
In January 2020, the company secured US$171m in new funding, which it said would allow the business to build a pilot production plant, expand its team and “hit a major milestone of launching products into the market”.
Uma Valeti, the company’s co-founder and chief executive, said at the time: “Memphis Meats is revolutionising how meat is brought to every table around the world. We are providing compelling and delicious choices by producing real meat from animal cells, its natural building blocks. Cell-based meat is poised to dramatically expand humanity’s capacity to feed a growing global population while preserving our culinary traditions and protecting our planet.”
It changed its name to Upside Foods in 2021.
A huge – US$105m – Series B funding round in July 2021 saw Brazilian meat giant BRF and Thai seafood heavyweight Thai Union Group among those backing Israel’s Aleph Farms.
Its other investors include private-equity firm L. Catterton and Cargill.
Aleph Farms’ total funding to date – July 2021 – now tops $118m.
BRF said the investment in Aleph Farms was in line with strategy of expanding into meat alternatives.
Aleph Farms said it would use the funds to scale-up manufacturing of its lab-created meat products and grow operations internationally ahead of initial market launch in 2022.
The company said it was working with regulatory agencies on its plans for market entry.
In November 2020, Aleph Farms, founded in 2017, said it had come up with a prototype for its first beef product.
“The company has developed five proprietary modules for its unique mass production platform, set to bring the product to cost parity with conventional meat at scale,” it said in a statement.
Co-founder and CEO Didier Toubia said: “One of the big challenges of cultivated meat is the ability to produce large quantities efficiently at a cost that can compete with conventional meat-industry pricing, without compromising on quality. We have developed five technological building blocks unique to Aleph Farms that are put into a large-scale production process, all patented by the company.”
Toubia founded Aleph Farms with the Israeli innovation programme The Kitchen Hub run by the Strauss Group, a local food manufacturer of dairy products, snacks and dips, along with Shulamit Levenberg, a professor at research university Technion – Israel Institute of Technology.
Aleph Farms is also working with Japan’s Mitsubishi Corp. on product development.
Planning to offer something different to cell-based steaks, burgers and sausages is France’s Gourmey, which is cultivating the delicacy foie gras in a lab.
It will also be creating lab-grown poultry products.
In July 2021, the Paris business bagged US$10m in seed funding and said it planned to scale up production and expected to launch commercially in 2022 or early in 2023.
Founded in 2019 by chief executive Nicolas Morin-Forest, technology officer Dr Victor Sayous and chief scientific officer Antoine Davydoff, Gourmey describes the products it is developing as “restaurant-grade meats”.
Morin-Forest said in a statement at the time the funding was announced: “Our mission is to re-imagine meat for our uncompromising and conscious generation so that we have a chance to feed ten billion people without devastating our environment.”
“We focus on cultivated meats that we can deliver at price and taste parity faster, which is the main challenge for the industry.”
Market-watchers will be interested to see if creating foie gras in a lab can end the cruelties inherent within the production process at the moment, notably the fattening of a goose’s liver. They will also be keen to see if foie gras-eating gourmets will take to something made in a lab.
There must be a perceived demand for such a product, though, as Japan’s IntegriCulture is also looking to make foie gras in a lab, as well as other meat products.
In May 2020, it was backed in a US$7.4m Series A funding round by a consortium including Japan’s NH Foods and investment company Beyond Next Ventures.
IntegriCulture said it would use the investment for research and development in cell-culture technology, facilities and equipment, staffing and operational costs.
The company explained its key aims were to bring cell-based foie gras to market next year (2021) and processed meat in 2023. It said it hoped to then start marketing cell-based beef in 2025.
Future Meat Technologies
In an area of food innovation not short of hyperbole, Israel’s Future Meat Technologies cranked things up another notch in June 2021 when it confidently predicted it would have products – made in a lab without the use of an animal serum growth medium – in the market by 2022.
Its claims were based on it opening the “world’s first” cultured meat production facility near Tel Aviv.
Calling the new facility a real “game-changer,” Future Meat Technologies’ founder and chief scientific officer, Professor Yaakov Nahmias, said “it “allows us to move out of the lab to grow hundreds of kilograms of meat in stainless steel vessels”.
He added: “Production is cleaner and more efficient. Most importantly, it allows us to speed up regulatory approval to aim for market [entry] by 2022.”
Future Meat, which at the same time revealed it had raised US$14m in a Series A funding round, said it planned to move into the US market by 2022 to sell through the foodservice channel.
Its first products could be hybrids of cell-based meat and plant-based ingredients.
Sceptics of the claims made by the company may have become more convinced when it was revealed a month later – in July 2021 – that the world’s largest food business, Nestlé, was exploring the possibility of developing cell-cultured meat products and had been working with Future Meat Technologies to make this happen.
US-based Eat Just, formerly just Just and before that Hampton Creek, can make a claim to have beaten everyone to the punch.
Although best-known for its-faux egg products, in December 2020 Eat Just revealed Singapore – which is actively backing the development of cell-based meat – had given its seal of approval for cultivated-meat products made by the Californian firm founded by entrepreneur Josh Tetrick.
In what is believed to be the world’s first regulatory approval for cell-based meat, the south-east Asian city-state’s regulator, the Singapore Food Agency (SFA), approved the sale of Eat Just’s hybrid “chicken bites” in a local restaurant. The products were sold commercially for the first time on 19 December.
The cells for its product are grown in a 1,200-litre bioreactor and then combined with plant-based ingredients.
At 7:03 pm Singapore time, cultured/cultivated meat made its historic commercial debut on the plates of 4 thoughtful kids and their inspiring teacher, @cpsillides.
The future of meat is here. pic.twitter.com/zFHv5s3PDA
— Josh Tetrick (@joshtetrick) December 19, 2020
In August 2021, Eat Just announced plans to build a cultivated-meat facility in Qatar. It claimed the plant, located in the Umm Alhoul Free Zone, is “the first-ever cultivated meat facility in the Middle East and Northern Africa (MENA) region”. The site will produce Eat Just’s Good Meat brand, with future plans to add a protein processing factory for its Just Egg products.
Ivy Farm Technologies
Ivy Farm Technologies, from the UK, revealed in June 2021 that it was targeting a second round of funding despite the fact it was just closing a GBP16m (US$22.6m) round.
The business, a spin-out from Oxford University, said the funding would facilitate additional research and development and help it near-double the size of its team from 29 to 50 before year-end.
Chief executive Rich Dillon, the former head of global sales at energy drink company Red Bull, told Just Food: “We are only weeks away from closing the funding round. The response has been very positive and we’ve got some great investors on board.
“We’re now looking forward to a Series A round at the end of the year.”
Ivy Farm was about to move into larger premises in Oxford, which will house “leading-edge equipment” and a bioreactor to help it scale up its manufacturing process which was proven with the production of a Cumberland sausage in December.
The next round of funding will pay for a “full-blown” pilot facility, which the company hopes will help it reach its goals of becoming the first British commercial producer of cultured meat.
Ivy Farm said it has developed a “unique” scaffold system to grow cells in a more efficient, faster and cheaper way than its rivals. It uses a plant-based growth medium.
The business was founded by Oxford University’s Dr Russ Tucker and Professor Cathy Ye in 2019.
Spain showed it had got skin in the cell-based meat game in January 2021 when the country part-funded a project in the country set up to develop cell-cultured meat products.
Biotech Foods, a firm based in San Sebastián in the north west of the country, is leading the scheme, which has attracted EUR3.7m (US$4.5m at the prevailing exchange rate) of government funding.
The company, developing alternatives to beef and pork, is the only cell-based firm involved in the project, in which Spanish meat processors Argal and Martínez Somalo are also taking part.
Iñigo Charola, Biotech Foods’ CEO, said the company had started pilot production but, asked when the company was hoping to launch its first product, he would only say: “We are working to bring our products to the market in the near term”.
He added: “Based on the successful launch of cultivated meat in Singapore we think cultivated meat will be part of our diets in many other countries sooner than expected.”
Charola went on: “BioTech Foods aims to commercialise its products globally. Product launch is our main priority at this moment and, as in most cases in the cultivated-meat industry, regulation and industrial scale production are the key challenges.”
In November 2021, it was announced that Brazilian meat giant JBS had taken a stake in BioTech and would be putting money into the development of its facilities.
After finalising its first “showcase product” – a pork sausage – in 2020, Netherlands-based Meatable said in March 2021 it would use the money raised from a newly-announced funding round to advance small-scale production at the Biotech Campus Delft and to diversify its product portfolio.
The US$47m Series A funding round took the total raised by the company to $60m.
Investors this time around included a consortium consisting of DSM Venturing, venture-capital fund Section 32 and doctors Rick Klausner and Jeffrey Leiden.
Meatable claims its “proprietary platform technology” enables a more cost-effective and scalable production process for cell-based meat without the use of a growth serum. It has previously said it hopes to have products ready by 2023.
New Age Meats
US-based New Age Meats is another firm that has caught the eye of investors.
In February 2021, it secured additional backing of US$2m from investors, including the founder of snack bar brand RXBar.
The Berkeley, California-based business, which specialises in lab-created pork products, has now been backed to the tune of $7m.
New Age Meats said it planned to use the new funding to “continue [the] construction of a team experienced in bringing products from inception to mass market”.
The company was founded in 2018 and is a graduate of IndieBio, a four-month accelerator programme based in California providing $250,000 to early stage biology start-ups.
Investors involved in the February funding round included “a very large, significant industry player in Asia” which, New Age Meats said, “for now must remain confidential” and Litani Ventures, the fund of RXBar snack bar founder Peter Rahal.
New Age Meats said it was now working to bring hybrid pork products, made from cultivated and plant-based ingredients, to market “soon”.
It pointed out that hires over the last year included not just bioengineers with product development and scaling experience but also a food team featuring “key Impossible Foods alumni”.
Brian Spears, the company’s CEO, said: “We’ve focused relentlessly on driving down the cost and scaling production of our product: hybrid cultivated and plant-based meat that doesn’t sacrifice on flavour.”
Creating lab-based beef is Switzerland’s Mirai, which raised US$2.4m in a seed funding round in January 2021.
Amongst its backers was Finland-based food-and-beverage company Paulig Group.
Marai said it would use the money to prepare for the commercialisation of its cultivated beef product.
Zurich-based Mirai, founded in 2019, suggests it is one of the few companies operating in this field that does not genetically manipulate the animal cells it uses to create meat products, which it predicts will be an important distinction for Europe-based consumers.
Speaking about the funding round, Christoph Mayr, Mirai co-founder and CEO, said: “We are proud to have such a strong and diverse pool of investors aboard for this journey.”
Marika King, head of Paulig’s venture arm PINC, said: “Mirai Foods is a second-generation player in this field and they have been extremely fast. It only took them six months to develop the first prototype and we are very excited to be part of this team’s journey.”
Amongst the first generation of cell-based meat firms is Israel’s SuperMeat.
Back in January 2018, it announced it had formed a strategic alliance with German poultry giant PHW-Gruppe which would help bring its “clean-chicken products” to market.
Based in Tel-Aviv, SuperMeat produces “clean meat” by growing cells extracted from chickens.
It attracted US$3m in seed funding in early 2018 and said at the time: “This process puts an end to the industrial need to mass-produce animals for slaughter, while eliminating exposure to animal waste and food-borne illnesses; the potential benefits for public health and animal welfare are therefore considerable.
“At the same time, clean meat is also highly beneficial for the environment, with drastically reduced carbon and ecological footprints compared to current meat production methods.”
US-based venture capital fund New Crop Capital and “mission-orientated” Stray Dog Capital led the round of funding.
Co-founder and chief executive Ido Savir said at the time: “We’re proud that SuperMeat is at the forefront of the rapidly-evolving clean-meat industry.”
After securing the funding, SuperMeat said it hoped to bring the product to market in the “very near future” and at a price similar to conventional chicken products.
In January 2021, US cell-based seafood firm BlueNalu was another start-up to attract the backing of a major name in food when it was revealed it Thailand-based seafood giant Thai Union had invested in the business.
The John West brand owner was among a number of new backers for the fledgling California-based firm which said it was looking to launch its first product later this year.
Thiraphong Chansiri, Thai Union’s president and CEO, said, “BlueNalu and its experienced team is at the forefront of cell-based seafood technology, with strong process capabilities to scale-up seafood in a sustainable manner. We are excited to work with them and look forward to exploring collaboration opportunities.”
BlueNalu, which has raised more than US$24m across seed and Series A financing, said the fresh investment would be used to it complete its pilot production facility and secure regulatory approval to launch its first product on a test basis in US foodservice establishments. The company said it was aiming to get a mahi mahi product on menus later in 2021 and was confident it would get regulatory approval for the move.
In an interview with Just Food in 2020, BlueNalu CEO and co-founder Lou Cooperhouse – a food industry veteran – described cell-based seafood as “the Holy Grail of the Holy Grail”.
In September 2021, the company announced it would start working with Nomad Foods, one of the largest suppliers of conventional seafood in Europe, to explore the potential of cell-based products in that region.
Singapore’s Shiok Meats suggests its first product – cell-based shrimp – will be brought to market in 2022.
In September 2020, it revealed plans to build its first manufacturing plant on the back of a new round of funding.
The fledgling business secured US$12.6m in a Series A investment round from a group of investors spread across Asia, Europe and the US, building on $4.6m of seed funding in 2019.
Netherlands-based investment fund Aqua-Spark, which is focused on sustainable aquaculture, led the round, with participation from 12 other investors.
Chief executive Dr. Sandhya Sriram, who founded Shiok Meats with its chief technology officer Dr. Ka Yi Ling in 2018, said: “The investors in this round, from all over the world, are all aligned towards one mission – sustainable, healthy, and delicious seafood for everyone.
“Our mission is to develop cell-based seafood and meats that are contributing towards a cleaner and healthier seafood industry and solving for the inefficiencies around global protein production.”
In July 2021, Shiok Meats announced new investment from South Korean food company CJ CheilJedang – which has invested in Aleph Farms earlier in the year – and from Vietnam seafood processor Vinh Hoan Corp., which was a backer of Hong Kong cell-seafood start-up Avant Meats.
Beyond the launch of frozen cell-based shrimp, Shiok Meats is planning to develop shrimp paste, a popular food ingredient in Asia, and cell-based lobster and crab products in “the coming years”.
In August 2021, Shiok announced that it was moving into cell-based meat with the acquisition of south-east Asian cultivated red meat start-up Gaia Foods.
Set up in 2018 to develop cell-cultured seafood, Avant Meats secured seed funding in November 2020 of more than US$3m, which included alternative-protein investment fund Lever VC and Markus Haefeli, the chairman of tilapia fish producer Regal Springs.
Avants Meats, headed by Carrie Chan, is focusing on being a business-to-business supplier of cell-cultured seafood. Chan sold a stake in the company to Vinh Hoan Corp., the Vietnam-based seafood processor in early 2021.
In April 2021, US cell-seafood start-up Cultured Decadence raised US$1.6m from a pre-seed round, It said it planned to put the money to work in developing cell-cultured lobster as it moves toward a commercial launch.
John Pattison, the firm’s CEO who has previously worked for US cell-based meat company New Age Meats, founded the business with chief scientific officer Ian Johnson in 2019 having come up with the idea to create sustainable seafood products with a “dramatically lower” environmental footprint.
Using its own technology, Cultured Decadence is developing seafood ‘meat’ using the cells of lobster in the first instance, with potential expansion into other shellfish such as crab, shrimp and scallops.
A spokesperson for the Madison, Wisconsin-based company, told just-food it does not yet have a manufacturing facility as the business is still at the R&D stage, adding: “We are currently building out our technology at bench scale and would look to pilot/commercialise in the next few years”.
Contributors to the pre-seed round included Chicago-based venture-capital fund Bluestein Ventures and peer Joyance Partners in San Francisco, along with Chinese investment firm Dao Foods.
Singapore’s TurtleTree Labs announced a new round of funding in December 2020 which it said would help it accelerate its plans to launch cell-based milk.
It was backed, to the tune of US$6.2m, by a consortium including existing investors Eat Beyond Global Holdings from Canada, US asset management firm KBW Ventures and Green Monday Ventures, the investment arm of plant-based food supplier Green Monday Group in Hong Kong. Verso Capital, a Luxembourg-headquartered investor, also took part in the funding round.
The Series A funding added to a previous $3.2m seed injection in June 2020.
TurtleTree said it planned to use the new funds for R&D and to expand its team as the company works with regulators to bring its debut product to market next year (2021).
The company claims to be the world’s first company using technology to create cell-cultured milk from animal cells. It was founded by chief executive Fengru Lin, chief scientific officer Rabail Toor, and chief strategist Max Rye.
Rye said in a statement at the time of its latest funding announcement: “The vision of TurtleTree Labs is to create a truly sustainable and cruelty-free food system. We are grateful to have the support of leading investors from every corner of the world.”
Biomilq, a fledgling US firm producing cell-cultured breastmilk, has attracted funding from big-name backers including an investor consortium that features Microsoft founder Bill Gates and Amazon’s Jeff Bezos, who happens to be the richest man on the planet.
The company, based in North Carolina, raised US$3.5m in its last funding round in June 2020, money it said would be used to “optimise” production, expand its team and work with families to paediatricians to bring its product to market.
Biomilq says it cultures mammary cells outside the body and, after producing human casein and lactose, believes it “can fully replicate the nutritional profile of breastmilk”.
Michelle Egger, co-founder and CEO of Biomilq, said: “While there is no replacement for breastmilk, we believe we can harness the power of science, technology, and nature to deliver comprehensive and sustainable infant nutrition.”